Ophthalmic insertion tool patent with integral scleral marker

USPTO published patent application US20260090911A1 by inventor James T. Perkins, covering an ophthalmic insertion tool with integral scleral marker. The application describes a device including a housing, cannula with distal tip and lumen, retractable sheath, and scleral markers positioned at distal and/or proximal ends of the housing. Application No. 18903180 was filed October 1, 2024.

Heating Garment Patent Application

USPTO published patent application US20260090910A1 for a heating garment filed by REB LLC (inventor: Katelyn Bray). The garment includes multiple heating elements disposed between two material layers with coupling mechanisms. CPC classifications indicate thermal therapy applications (A61F 7/02, A61F 7/007).

Face Masks with Therapeutic Cooling Patent Application

The USPTO published patent application US20260090909A1 for a face mask configured to provide therapeutic cooling using thermoelectric cooling devices such as Peltier elements. The invention generates heat flux at material junctions, creating cold and hot areas, with the cold side positioned toward the user's face. Inventors include Hannah Elizabeth Clark, Olivia Louise Parsons, Christopher W. Hedges, Christina J. Crowley, and Ellen Catherine Padula.

Personal Temperature Regulating Device and Wearable Garment

USPTO published patent application US20260090908A1 for a personal temperature regulating device comprising a wearable garment with an integrated temperature regulating membrane and control module. Inventors Michael Leland Frost and Adam Jacob Frost filed the application on September 25, 2025. The technology is classified under CPC A61F 7/007 and relates to personal thermal management systems.

PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of PRC2 inhibitor compounds for cancer treatment. Inventors: Mohammad AL-SAYAH and Robert Ronald MILBURN. Application filed September 13, 2023, classified under C07D 487/04 (heterocyclic compounds - organic chemistry). The patent covers the physical forms, pharmaceutical compositions, and methods of treating cancer by administering the compound.

Method for Preparing Amidines from N-(alkyl lactams) via Dehydration Catalysis

USPTO published patent application US20260092067A1 disclosing a method for preparing amidines from N-(amino-alkyl) lactams via dehydration using heterogeneous catalysts including cerium oxide, boron phosphates, zirconium compounds, and phosphotungstic acid. The application (No. 19108987) was filed September 4, 2023 and published April 2, 2026, listing inventors Nicola Vecchini and Federico Mondini. This represents a new synthetic route for amidine compounds used in pharmaceutical and fine chemical synthesis.

Novel synthetic routes for macrocyclic heterocycle manufacturing

USPTO published patent application US20260092066A1 on April 2, 2026, disclosing novel synthetic methods for preparing macrocyclic heterocycle intermediates. The application (filed June 18, 2025, Application No. 19242506) covers efficient methods for synthesizing key intermediates in the preparation of Compound (I) with broad substituent applicability.

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

Heterocyclic Compounds for Treatment of Disease

USPTO published patent application US20260092064A1 for heterocyclic compounds and compositions for treating disease, filed by inventors Raju Mohan, John Nuss, and Jason Harris on May 14, 2025. The application was published April 2, 2026, covering compounds classified under CPC codes including C07D 471/04, A61K 31/41, and A61P therapeutic categories.

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.